Matinas BioPharma Receives Notice of Non-Compliance with NYSE American Continued Listing Standards and Acceptance of Plan to Regain Compliance

Matinas faces imminent NYSE delisting risk after years of losses and shrinking equity.

What the company is saying

Matinas BioPharma Holdings, Inc. is disclosing that it has received a formal notice from the NYSE American LLC regarding non-compliance with continued listing standards. The company’s core narrative is strictly factual: it is not meeting the required stockholders’ equity thresholds due to sustained losses over multiple years. The announcement emphasizes the precise regulatory breaches—specifically, falling below the $4.0 million and $6.0 million equity requirements under Sections 1003(a)(ii) and 1003(a)(iii) of the NYSE American Company Guide. The language is clinical and regulatory, with no attempt to soften the impact or offer reassurance to investors. There are no forward-looking statements, no mention of remedial actions, and no commentary from management, which is notable for its absence. The company does not highlight any operational achievements, strategic initiatives, or plans to regain compliance, effectively burying any sense of future direction. No notable individuals are referenced, and there is no attempt to frame the situation as temporary or manageable. This communication fits a minimalist, compliance-driven investor relations strategy, focused solely on regulatory disclosure rather than narrative management or investor engagement. Compared to typical corporate communications, the lack of optimism, leadership commentary, or remedial plans marks a significant shift toward bare-minimum disclosure.

What the data suggests

The disclosed numbers paint a stark picture of financial deterioration. As of December 31, 2025, Matinas reported stockholders’ equity of $4.83 million, already below the $6.0 million threshold required for companies with five years of consecutive losses. By March 31, 2026, equity had fallen further to $3.02 million, now also below the $4.0 million threshold for companies with three years of losses. This represents a $1.81 million drop in equity in a single quarter, a steep decline that signals accelerating financial distress. The company has reported losses in each of the five most recent fiscal years, confirming a persistent inability to generate profits or stabilize its capital base. There is no evidence of meeting prior targets or reversing the negative trend; instead, the data confirms ongoing and worsening non-compliance. The financial disclosures are limited but clear—key metrics like revenue, cash flow, or operational expenses are omitted, making it impossible to assess the underlying business health beyond equity erosion. An independent analyst would conclude that the company is in a precarious position, with shrinking equity, no sign of profitability, and no disclosed plan to address the situation. The numbers alone suggest a high risk of delisting and further value destruction.

Analysis

The announcement is a factual disclosure of non-compliance with NYSE American listing standards, supported by specific, dated equity figures and a clear record of losses. There are no forward-looking statements, projections, or aspirational claims; all information pertains to realised events and current financial status. The language is neutral and regulatory in tone, with no attempt to frame the situation positively or to inflate the company's prospects. There is no mention of capital outlays, remedial plans, or future benefits, so no hype or narrative inflation is present. The gap between narrative and evidence is nonexistent, as the announcement strictly adheres to the facts. No promotional or exaggerated language is used.

Risk flags

• ●Delisting risk is acute: The company has received a formal notice of non-compliance from the NYSE American, and is now subject to Section 1009 procedures. Delisting would severely impact liquidity, investor access, and potentially trigger debt covenants or other adverse events.
• ●Persistent multi-year losses: Matinas has reported losses in each of the five most recent fiscal years, indicating a chronic inability to achieve profitability. This pattern raises fundamental questions about the viability of the business model and management’s ability to reverse the trend.
• ●Rapid equity erosion: Stockholders’ equity fell from $4.83 million at year-end 2025 to $3.02 million by March 31, 2026—a $1.81 million decline in just one quarter. Such a steep drop suggests accelerating cash burn or asset impairment, increasing the risk of insolvency.
• ●No disclosed remediation plan: The announcement contains no mention of capital raising, cost-cutting, asset sales, or other measures to restore compliance. The absence of a plan leaves investors with no basis for optimism or recovery.
• ●Limited financial disclosure: Only equity and loss history are provided, with no detail on revenues, cash flows, or operational metrics. This lack of transparency makes it difficult for investors to assess the underlying causes of financial distress or the company’s ability to recover.
• ●Immediate regulatory pressure: The company is now subject to NYSE American’s Section 1009 procedures, which typically impose strict timelines for remediation. Failure to act quickly could result in forced delisting, further eroding shareholder value.
• ●No leadership visibility: There is no commentary from management or identification of responsible executives, which may signal either a lack of strategy or unwillingness to engage with investors during a crisis. This absence undermines confidence in governance and oversight.
• ●All claims are realized, not forward-looking: While this reduces narrative risk, it also means there is no articulated path to improvement—investors are left with only negative facts and no stated plan for change.

Bottom line

For investors, this announcement is a clear warning signal: Matinas BioPharma Holdings, Inc. is at immediate risk of being delisted from the NYSE American due to sustained losses and rapidly declining equity. The company’s financial trajectory is negative, with equity dropping by $1.81 million in a single quarter and no sign of profitability over five years. There is no evidence of a turnaround plan, capital infusion, or operational improvement—only a factual admission of non-compliance. The lack of management commentary or remedial disclosure leaves investors in the dark about any potential for recovery. No notable institutional figures or insiders are referenced, so there is no external validation or implied support. To change this assessment, the company would need to disclose a credible, fully funded remediation plan—such as a binding capital raise, cost restructuring, or strategic partnership—along with detailed financials showing a path to compliance. In the next reporting period, investors should watch for any updates on remediation efforts, changes in equity, or further regulatory actions. Given the immediacy and severity of the risks, this is not a signal to buy or hold, but rather a situation to monitor closely or avoid until there is clear evidence of stabilization. The single most important takeaway: without swift, concrete action, Matinas faces a high probability of delisting and further value destruction.

Announcement summary

(NYSE: MTNB) Matinas BioPharma Holdings, Inc. announced that on June 24, 2026, it received a notice from the NYSE American LLC stating that the Company is not in compliance with the NYSE American continued listing standards set forth in Section 1003(a)(ii) of the NYSE American Company Guide, which requires stockholders’ equity of at least $4.0 million if the company has reported losses from continuing operations and/or net losses in three of its four most recent fiscal years. As of March 31, 2026, the Company had stockholders’ equity of $3.02 million and has had losses in the most recent five fiscal years ended December 31, 2025. The Company is also not in compliance with Section 1003(a)(iii) of the Company Guide, which requires stockholders’ equity of at least $6.0 million if it has reported losses in its five most recent fiscal years. As of December 31, 2025, the Company had stockholders’ equity of $4.83 million and has had losses in the most recent five fiscal years ended December 31, 2025. Due to its non-compliance with Sections 1003(a)(ii) and 1003(a)(iii), the Company is subject to the procedures and requirements of Section 1009 of the Company Guide. No forward-looking statements or projections are included in the source text.

Disagree with this article?